NASDAQ · Biotechnology · USD

Parabilis Medicines, Inc. (PBLS) Stock Analysis

Parabilis Medicines, Inc. (PBLS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PBLS

$40.42

−$0.33 (−0.81%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PBLS with… →

PBLS Key Statistics

As of Sep 4, 2026

Trading

Open: $40.20
Previous Close: $40.75
Day's Range: 39.50–41.19
52-Week Range: 24.51–41.49
Volume: 380.70K

Valuation

Market Cap: $4.99B
P/E Ratio: unprofitable
EPS (ttm): −1.86

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$145.89M
Profit margin: 0.00%
Shares Outstanding: 121.95M

Dividend and dates

Earnings Date: November 12, 2026estimated
Avg Volume: 648.07K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PBLS Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$145.89M	—
2024	$0.00	−$117.91M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$152.08M	−$145.89M	—
2024	$0.00	—	−$126.13M	−$117.91M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PBLS Valuation vs Biotechnology Median

Median of 656 stocks

Metric	PBLS	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Parabilis Medicines, Inc. (PBLS) is capitalised at $4.99B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 145.

PBLS last closed at $40.42 on September 4, 2026. That is −$0.33 (−0.81%) against the previous close. Over the past 52 weeks the price has ranged from $24.51 to $41.49. The latest close sits 64.91% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $145.89M. Profit margin runs at 0%. Trailing earnings per share are −1.86.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

The record shows no dividend for PBLS.

2026 is still running; the price is +27.91% year to date.

Peer Comparison

Parabilis Medicines, Inc. (PBLS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Parabilis Medicines, Inc.	PBLS	$4.99B	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Parabilis Medicines, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Parabilis Medicines, Inc.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Visit website →